SKYE Valuation
Skye Bioscience Inc
$
3.270
- Overview
- Forecast
- Valuation
- Earnings
SKYE Relative Valuation
SKYE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SKYE is overvalued; if below, it's undervalued.
Historical Valuation
Skye Bioscience Inc (SKYE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.18. The fair price of Skye Bioscience Inc (SKYE) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：3.14
Fair
-2.50
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Skye Bioscience Inc. (SKYE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.16
EV/EBIT
Skye Bioscience Inc. (SKYE) has a current EV/EBIT of -1.16. The 5-year average EV/EBIT is -1.82. The thresholds are as follows: Strongly Undervalued below -7.48, Undervalued between -7.48 and -4.65, Fairly Valued between 1.01 and -4.65, Overvalued between 1.01 and 3.84, and Strongly Overvalued above 3.84. The current Forward EV/EBIT of -1.16 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Skye Bioscience Inc. (SKYE) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-2.93
P/OCF
Skye Bioscience Inc. (SKYE) has a current P/OCF of -2.93. The 5-year average P/OCF is -1.96. The thresholds are as follows: Strongly Undervalued below -9.56, Undervalued between -9.56 and -5.76, Fairly Valued between 1.84 and -5.76, Overvalued between 1.84 and 5.64, and Strongly Overvalued above 5.64. The current Forward P/OCF of -2.93 falls within the Historic Trend Line -Fairly Valued range.
-2.94
P/FCF
Skye Bioscience Inc. (SKYE) has a current P/FCF of -2.94. The 5-year average P/FCF is -1.95. The thresholds are as follows: Strongly Undervalued below -9.46, Undervalued between -9.46 and -5.71, Fairly Valued between 1.80 and -5.71, Overvalued between 1.80 and 5.55, and Strongly Overvalued above 5.55. The current Forward P/FCF of -2.94 falls within the Historic Trend Line -Fairly Valued range.
Skye Bioscience Inc (SKYE) has a current Price-to-Book (P/B) ratio of 2.31. Compared to its 3-year average P/B ratio of -4.56 , the current P/B ratio is approximately -150.61% higher. Relative to its 5-year average P/B ratio of 2.12, the current P/B ratio is about 8.88% higher. Skye Bioscience Inc (SKYE) has a Forward Free Cash Flow (FCF) yield of approximately -32.13%. Compared to its 3-year average FCF yield of -42.86%, the current FCF yield is approximately -25.05% lower. Relative to its 5-year average FCF yield of -38.38% , the current FCF yield is about -16.31% lower.
2.31
P/B
Median3y
-4.56
Median5y
2.12
-32.13
FCF Yield
Median3y
-42.86
Median5y
-38.38
Competitors Valuation Multiple
The average P/S ratio for SKYE's competitors is 26.47, providing a benchmark for relative valuation. Skye Bioscience Inc Corp (SKYE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SKYE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SKYE in the past 1 year is driven by Unknown.
People Also Watch
AUBN
Auburn National Bancorporation Inc
26.860
USD
-0.15%
CBAT
CBAK Energy Technology Inc
0.988
USD
-1.69%
ASRT
Assertio Holdings Inc
0.818
USD
+0.74%
XCH
XCHG Ltd
1.180
USD
+4.42%
NA
Nano Labs Ltd
4.500
USD
+2.27%
PED
PEDEVCO Corp
0.620
USD
+0.16%
CAPN
Cayson Acquisition Corp
10.350
USD
-0.29%
VIGL
Vigil Neuroscience Inc
8.060
USD
0.00%
EDAP
Edap Tms SA
1.350
USD
+0.75%
FAQ
Is Skye Bioscience Inc (SKYE) currently overvalued or undervalued?
Skye Bioscience Inc (SKYE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.18. The fair price of Skye Bioscience Inc (SKYE) is between to according to relative valuation methord.
What is Skye Bioscience Inc (SKYE) fair value?
How does SKYE's valuation metrics compare to the industry average?
What is the current P/B ratio for Skye Bioscience Inc (SKYE) as of Aug 14 2025?
What is the current FCF Yield for Skye Bioscience Inc (SKYE) as of Aug 14 2025?
What is the current Forward P/E ratio for Skye Bioscience Inc (SKYE) as of Aug 14 2025?